Beroni Group, an international diversified biopharmaceutical enterprise, has provided an update on the development of the previously announced potential medical solution utilizing nanobody technology for both detection and treatment of COVID-19 in collaboration with Tianjin University in China.   After identifying the 24 specific nanobodies with high affinity to the new coronavirus N- protein and S-protein antigens through high-throughput screening in May 2020, the scientific team has used struc...